Novel UHPLC-MS/MS method for the determination of rotigotine in the plasma of patients with Parkinson's disease.
A novel ultra-high-pressure liquid chromatography-tandem mass spectrometry method was developed and validated for the determination of the dopamine receptor agonist rotigotine in human plasma. Following liquid-liquid extraction with tert-butyl methyl ether from 500 μL plasma, the chromatographic analysis was performed on a Gemini NX3 column using 5 mm pH 5.0 ammonium acetate-5 mm ammonium acetate in methanol as binary gradient mobile phase, at a flow rate of 0.3 mL/min. The MS/MS ion transitions were 316.00 → 147.00 for rotigotine and 256.10 → 211.00 for the internal standard (lamotrigine). The lower limit of quantitation was 50 pg/mL and the linearity was determined from 50 to 2500 pg/mL. The mean recovery was 96.9%. Both intra- and interassay imprecision and inaccuracy were ≤15% at all quality control concentrations. The method was successfully applied to measure morning trough plasma rotigotine concentrations in a series of patients with Parkinson's disease on chronic treatment. The present study describes the first fully validated method for rotigotine determination in human plasma.
IRCCS-ISNB Institute of Neurological Sciences of Bologna, Italy.
Susan
S
Mohamed
IRCCS-ISNB Institute of Neurological Sciences of Bologna, Italy.|Department of Biomedical and Neuromotor Sciences University of Bologna, Bologna, Italy.
Roberto
R
Riva
IRCCS-ISNB Institute of Neurological Sciences of Bologna, Italy.|Department of Biomedical and Neuromotor Sciences University of Bologna, Bologna, Italy.
Manuela
http://orcid.org/0000-0001-6399-9999
M
Contin
D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D018491:Dopamine Agonists / Q000097:blood* / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D057230:Limit of Detection; D016014:Linear Models; D010300:Parkinson Disease / Q000188:drug therapy*; D015203:Reproducibility of Results; D053719:Tandem Mass Spectrometry / Q000379:methods*; D013764:Tetrahydronaphthalenes / Q000097:blood* / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D013876:Thiophenes / Q000097:blood* / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use
D018491:Dopamine Agonists; D013764:Tetrahydronaphthalenes; D013876:Thiophenes; C047508:rotigotine
Parkinson's disease; UHPLC-MS/MS; dopamine receptor agonist; rotigotine